Since radiation from 225Ac-DOTA-CD38 TAT accumulated in the tumor could indirectly affect the anti-MM activity of CS1 CAR T cell viability infiltrated in the tumor site, a preliminary TAT treatment schedule of 14 days post CAR T cell therapy was investigated. This evidence concerns the gene CD38 and Miyoshi myopathy.